<DOC>
	<DOC>NCT01845688</DOC>
	<brief_summary>The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.</brief_summary>
	<brief_title>Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, Membranous</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Women and men who had a clinic and biopsyproven idiopathic membranous nephropathy; 6.0g≥24 hour urinary protein≥1.0g; serum albumin concentration≥26g/L; Chronic Kidney Disease (CKD)≤3 stage (eGFR＞30ml/min/1.73m2 MDRD); Willing to participate in the trial and signed an informed consent. Secondary membranous nephropathy; Patients with one of the following circumstances malignant tumors or malignancy, HIV infection, a history of mental illness, any serious systemic infection, serious gastrointestinal diseases, circulating hepatitis B surface antigens positive or persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes mellitus; Pregnant and lactating women; Undergoing other clinical trials.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Idiopathic Membranous Nephropathy</keyword>
	<keyword>Traditional Chinese Medicine</keyword>
	<keyword>Randomized Control Trial</keyword>
</DOC>